Summary The glycolipid content of human non-seminomatous germ cell tumour cell lines correlates with their differentiation lineage. To analyse whether this reflects the situation in primary tumours, we studied five embryonal carcinomas, five yolk sac tumours and nine (mixed) non-seminomas, using thin-layer chromatography and carbohydrate immunostaining. We also analysed the glycolipid content of 19 seminomas to reveal their relationship with non-seminomas. Lactosylceramide (CDH) was detected in all embryonal carcinomas, but in fewer than half of the seminomas. Seminomas and embryonal carcinomas contained globoseries glycolipids, including globotriosylceramide (Gb3), globoside (Gb4), galactosyl globoside (Gb5) and sialyl galactosyl globoside (GL7). The lacto-series glycolipid Lex was found in all embryonal carcinomas, but only in one seminoma. Gangliosides GD3 and GT3 were detected in many seminomas, but rarely in embryonal carcinomas. Yolk sac tumours displayed a heterogeneous glycolipid profile. Compared with seminomas and pure embryonal carcinomas, differentiated non-seminomas had reduced levels of globo-series glycolipids, especially Gb3 and Gb5, whereas CDH, Lex, GD3 and GT3 were found in the majority of cases. Thus, the glycolipid content of non-seminoma cell lines reflects the situation in primary tumours. Globo-series glycolipids are similarly expressed in seminomas and embryonal carcinomas. The expression of Gb3 and Gb5 is reduced in non-seminomas upon differentiation. Lex expression in non-seminomas, including embryonal carcinomas, allows discrimination from seminomas. Expression of gangliosides in seminomas might indicate their maturation from ganglioside-negative precursor cells. Reprogramming of these precursors would result in the formation of Lex-expressing embryonal carcinomas.
In humans, two entities of testicular germ cell tumours (TGCTs) of adolescents and adults can be distinguished: seminomas (SEs), which are composed of tumour cells that are considered to be the malignant counterpart of human primordial germ cells, and non-seminomatous TGCTs (NSs), comprising embryonal carcinoma (EC, the undifferentiated stem cells of human NSs), immature and mature teratoma (IT and MT), yolk sac tumour (YS) and choriocarcinoma (CC) (Mostofi et al., 1987) . The relationship between SEs and NSs is a matter of debate. Several investigators suggest that SE and NS are biologically independent (Pierce and Abell, 1970; Mostofi, 1984; Sesterhenn, 1985) , whereas others assume that NS develops through a, not necessarily clinically manifest, SE stage (Friedman, 1951; Oliver, 1987; Oosterhuis et al., 1989; Oosterhuis and Looijenga, 1993) . According to this so-called linear progression model, SE cells become 'reprogrammed' to EC cells. This hypothesis is supported by morphological, ultrastructural, immunohistochemical (interphase), chromosomal and clinical analyses (Oosterhuis et al., 1989; De Jong et al., 1990; Oliver, 1990; Czernobilsky, 1991; Fossa et al., 1991; Czaja and Ulbright, 1992; El-Naggar et al., 1992; Looijenga et al., 1993) .
The study of human NSs is facilitated by the existence of cell lines representing most non-seminomatous cell types (Pattillo et al., 1971; Fogh and Trempe, 1975; Andrews et al., 1980; Oosterhuis et al., 1985; Casper et al., 1987; Pera et al., 1987; Damjanov et al., 1993; Keitz et al., 1995) . Experiments can be performed using cell lines of pluripotent EC cells, which can be induced to differentiate by exposure to certain agents (e.g. retinoic acid and hexamethylene bisacetamide), for example allowing analysis of changes in gene expression responsible for, or coinciding with, the process of differentiation. Some of these studies have focused on the expression of cell-surface glycolipids, i.e. molecules composed of a carbohydrate and a lipid moiety. Various groups of glycolipids can be distinguished according to their basic molecular structure (IUPAC-IUB, 1978) . The three main groups are the so called globo-, lacto-, and ganglio-series glycolipids (Svennerholm, 1964) . Among others, glycolipids are involved in early embryonic development and in mediation/modification of growth factor action (Bird and Kimber, 1984; Bremer et al., 1984; Fenderson et al., 1984; Cuello et al., 1989; Eggens et al., 1989) . Therefore, glycolipids might be important in the development of TGCTs. The patterns of glycolipid expression in non-seminomatous cell lines correlate with their differentiation lineage. Andrews et al. (1990) and Wenk et al. (1994) have shown that EC cell lines are characterised by the expression of globo-series glycolipids, including globotriosylceramide (Gb3), globoside (Gb4), galactosylgloboside (Gb5) and sialyl galactosylgloboside (GL7). Upon induced or spontaneous differentiation of these cells into the various non-seminomatous cell types the synthesis of globo-series glycolipids is down-regulated, whereas the synthesis of lacto-, and ganglio-series glycolipids (including Lex, and GD3/GT3 respectively) increases. Cell lines derived from YSs can contain Gb3, Gb4 and gangliosides, whereas CC cell lines mainly express Gb3 and the stage-specific embryonic antigen 1 (SSEA-1)-carrying lacto-series glycolipid Lex (Wenk et al., 1994) . Thus, specific combinations of glycolipids are correlated with specific cell types and the way in which the various cell types are related can be studied using glycolipid analysis. No extensive data on the glycolipid pattern of primary SEs and NSs have been reported (Ohyama et al., 1990 (Ohyama et al., , 1992 Galfll-+4Glcfl-4Cer
Lacto-series Galfl-+4GlcNAcfll-3Galfll---4Glcfl->Cer
aGlobo-series glycolipids contain Galal--4Gal; lacto-series glycolipids contain GlcNAcil->3Gal; ganglio-series contain NeuAca2--3Gal. bNo antibodies to detect CMH and CDH are available; these molecules are detected using orcinol staining. 135 migration with pure glycolipid standards and by immuno staining with specific monoclonal anti-carbohydrate antibodies (Fenderson et al., 1987; Andrews et al., 1990) . In brief, 5 il of each glycolipid sample was streaked onto Whatman HP-FK silica gel plates and subjected to ascending chromatography using a solvent system of chloroformmethanol-water (50:40:10 v/v/v) containing 0.05% (w/v) calcium chloride. After drying, the chromatography plates were coated with 0.5% (w/v) polyisobutylmethacrylate (Aldrich, Milwaukee, MI, USA) in diethyl ether for 1 min, blocked for 2 h with 5% bovine serum albumin (BSA) (Sigma, St Louis, MO, USA) in phosphate-buffered saline (PBS), and then reacted with primary antibody overnight at 4°C. Bound antibody was detected using a 2 h incubation at 4°C with alkaline phosphatase-conjugated goat anti-mouse antibody (HyClone, Logan, USA) diluted 1:1000. Colour reaction was obtained through incubation with bromochloroindolyl phosphate (Fisher Biotech, NJ, USA) and nitroblue tetrazolium (Sigma) for 1 h at room temperature (Harlow and Lane, 1988) .
Monoclonal antibodies Anti-carbohydrate monoclonal antibodies (MAbs) were obtained and used as described previously (Fenderson et al., 1987) . Gb3 was detected using MAb IA4-E1O (Fenderson et al., 1987) ; Gb4 and Gb5 were detected using MAb MC630 to SSEA-3 (Kannagi et al., 1983a) ; GL7 was detected using MAb MC813 to SSEA-4 (Kannagi et al., 1983b) ; Lex was detected using MAb MC480 to SSEA-1 (Solter and Knowles, 1978; Gooi et al., 1981) ; GD3 was detected using MAb R-24 (Dippold et al., 1984) ; GT3 was detected using MAb A2B5 (Eisenbarth et al., 1979) . The glycolipid carbohydrate structures recognised by these reagents are listed in Table I .
Orcinol
Gangliosides are designated according to the nomenclature of Svennerholm (1964) . Glycolipids are designated according to the recommendations of the IUPAC Nomenclature Committee (IUPAC-IUB, 1978) . Results Glycolipid profiles of tymphocyte-depleted seminoma cell suspensions SEs are known to contain infiltrating lymphocytes (Mostofi, 1980 (Mostofi, , 1984 , which could influence our tumour glycolipid analysis. Therefore, magnetic anti-CD2 coated beads were used to remove these inflammatory cells from SE cell suspensions. Thin-layer chromatography and subsequent orcinol or immunostaining for SSEA-1, SSEA-3 and SSEA-4, using pellets of either untreated or lymphocyte-depleted cells, revealed that lymphocyte depletion did not result in a marked change in glycolipid profile (Figure 1) . Orcinol staining revealed an additional band of unknown origin in the bead-treated samples that did not react with any of the MAbs included in this study. Whether this band is specific for SEs needs further investigation. Gb3 and Gb4 were the major glycolipids in all five SE samples. Two tumours, TL1049 and TL3544, were found to have high levels of glycolipid expression. These tumours contained an extended GL7 glycolipid, referred to as GL9, previously shown to be present in NT2 cells (Andrews et al., 1990) . Figure 2 . All data concerning the glycolipid profiles of the 50 analysed samples are listed in Table II and summarised in Table III. Compared with normal testicular parenchyma, CIScontaining parenchyma was characterised by the abundant presence of Gb3 and Gb5, and an increase in the expression of Gb4 and GL7.
Of 21 SEs analysed, all tumours expressed the globo-senes glycolipid GL7, whereas CDH was found in nine, Gb3 and Gb4 in 19 and Gb5 in ten SEs. The ganglio-series glycolipids GD3 and GT3 were present in 14 and ten SEs respectively. The expression level of the distinct glycolipids varied among the SEs. With regard to GL7 in particular, two groups of SEs could be distinguished: one with a low and one with a high level of expression. Since tumour cell enrichment by lymphocyte depletion did not result in a marked change in detection levels of the glycolipids and similar-size tumour blocks were used for glycolipid extraction, the high and low glycolipid levels found in the tumour blocks apparently reflect differences in expression level and not a variation in the amount of tumour cells present in each sample.
In contrast to the SEs, only one of which expressed Lex, all ECs contained this marker. CDH and Gb5 were also present in all ECs. These tumours further expressed Gb3, Gb4 and GL7 in all samples, as did the majority of the SEs. Two ECs were found to weakly express GD3, whereas only one tumour contained GT3.
The YSs did not display a clearly defined glycolipid profile. One tumour expressed Gb3, Gb4, GbM, GL7 and Lex. Two tumours expressed Gb3, Gb4 and GD3, either in combination with Lex or GT3. One tumour expressed Gb5, GL7, Lex and GD3. Two YSs completely lacked all four globo-series glycolipids: one contained Lex only, while the other, derived from a xenografted mixed tumour, had GD3 and GT3.
Compared with SEs and ECs, the nine (mixed) NSs had reduced levels of globo-series glycolipids, especially Gb3 and Gb5, whereas CDH and Lex were found in the majority of the samples. Eight NSs contained GD3 and GT3. The highest ganglioside levels were found in tumours with at least an MT component. The pure MT had trace amounts of Gb3, Gb4 and GL7, besides high levels of GD3 and GT3.
The SS did not express GL7 and Lex. The dermoid cyst contained Gb3, Gb4, GL7, GD3 and GT3. One B-cell lymphoma contained some CDH, whereas the other had low levels of CDH, Gb4, GL7 and Lex.
Discussion
We analysed whether the glycolipid content of human NS cell lines reflects the situation in primary tumours, using thinlayer chromatography and carbohydrate immunostaining. We DCDH Gb3 Gb4 Figure 2 Thin-layer chromatography immunostaining analysis of globo-series glycolipid expression in lower phase and upper phase extracts of human testicular germ cell tumours. Glycolipid standards are included on the right side of each plate (S). Plates were developed with chloroform-methanol-water (50:40:10) containing 0.05% calcium chloride and either stained for carbohydrate using Orcinol (upper phase) or labelled with monoclonal antibody directed to SSEA-3 (middle phase) or SSEA4 (lower phase).
Results represent bound antibody detected using alkaline phosphatase-conjugated second antibody. Samples are identified by number in Table II. also analysed the glycolipid content of CIS and SEs, particularly to reveal the relationship of the latter with ECs. SEs and testicular parenchyma containing CIS were characterised by similar glycolipid patterns. This result attests to the phenotypic similarity of CIS and SE cells.
As expression of gangliosides is regarded as a marker of differentiation (Fenderson et al., 1987) 2, + 7, + The number of samples (of the total number analysed, indicated in brackets) expressing the indicated marker and the average immunostaining intensity are shown. Glycolipid structures were identified in this report by: (i) co-migration on thin-layer chromatography plates with pure glycolipid standards and (ii) by immunostaining using specific anti-glycolipid monoclonal antibodies. CIS, carcinoma in situ-containing testicular parenchyma; EC, embryonal carcinoma; N, normal testicular parenchyma; NS, non-seminomatous testicular germ cell tumour; SE, seminoma; YS, yolk sac tumour. a Four YSs contained minor amounts of other non-seminomatous cell types, as indicated in Table II . The results of a testicular Wilms' tumour were not included in the average staining intensity of non-seminomas. Expression is from absent (no symbol) to strong (+ + +).
cells that express globo-series glycolipids only. Whether primordial germ cells, the benign counterparts of SE cells, also show heterogeneity concerning glycolipid expression could be analysed in future studies, using immunohistochemistry.
Two tumours, TL1049 and TL3544, were found to have high levels of glycolipid expression and contained an extended GL7 glycolipid, referred to as GL9, previously shown to be present in NT2/D1 cells (Andrews et al., 1990) . Interestingly, these tumours have previously been shown to contain a mutant ras gene (Olie et al., 1995a) and exhibit an aberrant in vitro behaviour (Olie et al., 1995b) . Sixteen other SEs, comprising three ras mutant and 13 wild-type tumours, showed no correlation between the presence of a ras mutation and high glycolipid expression, while none of these ras mutant SEs expressed GL9.
No SE cell lines are available at present, although one cell line, designated S2, has been described to have some seminomatous characteristics (von Keitz et al., 1995) . Analysis of the glycolipid profile revealed that S2 cells contain some Gb3, but mainly express CDH, Gb4, GL7 and Le', while Gb5 is not present (Wenk et al., 1994) . We confirmed the reported data on S2 in a blind test during this study, which allowed identification of the S2 origin of the sample (not shown). In combination with our findings of CDH and Lex mainly in primary ECs (see below), and the absence of Gb5 in half of the SEs, the suggestion that S2 represents a tumour cell with an intermediate phenotype between SE and EC, but not a pure SE (Wenk et al., 1994; von Keitz et al., 1995) , is supported.
All SEs (except one) lacked Lex, while this glycolipid was present in all ECs. This marker can thus be used for the differential diagnosis between SE and EC. In primary ECs, the expression of CDH is markedly enhanced, as compared with cell lines. This could mean that CDH is more rapidly converted into the derived globo-series glycolipids in cell lines cultured in vitro, especially as the expression of globo-series glycolipids is similar in primary tumours and cell lines.
Results obtained in a NATO advanced study workshop (Andrews et al., 1996) on the expression of cell-surface antigens by TGCT cell lines, applying immunohistochemistry and immunoflow cytometry, largely confirm our data on Lex, detected with antibodies to SSEA-1 (as well as those on SSEA-3 and SSEA-4 expression). However, our data and those presented by Wenk et al. (1994) show some differences with those obtained by Andrews et al., (1996) . The latter detected SSEA-1 antigen on all cells from the EC cell lines H12.1 and H12.2, whereas Wenk et al., 1994 could not detect this marker on these cell lines, using glycolipid analysis. Most likely, this is due to the fact that although SSEA-1 antigen can be carried on glycolipids, it is mainly presented at the cell surface as glycoprotein (Fenderson et al., 1993 (1982) might account for their findings, as they also failed to detect SSEA-3 expression in SEs (using the two-step approach), which was detected by us in the present study and in an immunohistochemical analysis using the avidin-biotin method (not shown).
The glycolipid patterns of the two pure YSs, TL1013 and TL37R21, the latter derived from a xenografted NS with a YS component, are similar to those described for YS cell lines. The four primary YSs with minor populations of other non-seminomatous cell types (as indicated in Table IL Our data on the spermatocytic seminoma support the contention that this tumour type is a separate GCT entity. not derived from CIS cells (Burke and Mostofi. 1993; Cummings et al., 1994) . Based on their glycolipid content. the spermatocytic seminoma, non-GCTs and the normal parenchyma of the testis could readily be discriminated from TGCTs and parenchyma containing CIS.
In conclusion, our analysis of the glycolipid content of human primary TGCTs confirms the data obtained on nonseminomatous cell lines (Wenk et al., 1994) . Globo-series glycolipids are highly expressed in ECs, whereas the expression of especially Gb3 and Gb5 is reduced in differentiated non-seminomatous elements. In addition. we show that the globo-series glycolipids are expressed at similar levels in CIS. SEs and ECs. The expression of LeX by ECs allows discrimination between this tumour type and SEs. which do not express this marker. Gangliosides are found in many SEs and almost all differentiated NSs. but are rare in ECs. These results could be integrated in the speculative model shown in Figure 3 
